Subscribe To

Price Alert Latest News Economic Calendar News

HUGE / FSD Pharma plans buyback of up to 1.9 million shares to utilize cash reserves

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said its board of directors has approved a share repurchase program that will allow the company to buy back up to 1.9 million of its subordinate Class B voting shares over the next 12 months. “FSD Pharma is focused on the advancement of its drug candidates toward the clinic, and we recognize there may be a strategic opportunity to enhance shareholder value without compromising our ambitious growth plans,” the company's interim CEO Anthony Durkacz said in a statement. Read More

Demo Live Account See Partner Details

Content Topics

Pharma

Plans

Buyback

Million

Utilize

Cash

Reserves

Stock

HUGE

Posted: Jan 13 2023, 09:46

Author Name: Proactive Investors

HUGE News

By Accesswire
August 15, 2023

FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023

Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment Market TORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma Inc. (NASDAQ:HU

By Proactive Investors
January 30, 2023

FSD Pharma says recruiting underway in Phase 2 Trial of FSD201 for treating chronic pain associated with idiopathic MCAS

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said recruiting is underway for the Phase 2 clinical trial of FSD-PEA (FSD201) for the treatment of chronic p

By Proactive Investors
January 17, 2023

FSD Pharma submits clinical trial application for its multiple sclerosis treatment candidate Lucid-MS

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) announced it has submitted a Clinical Trial Application (CTA) for a planned Phase-1 clinical trial for Lucid-MS

By Proactive Investors
January 13, 2023

FSD Pharma plans buyback of up to 1.9 million shares to utilize cash reserves

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) said its board of directors has approved a share repurchase program that will allow the company to buy back up

By Proactive Investors
January 9, 2023

FSD Pharma incorporates new subsidiary to capitalize on drug development incentives in Australia

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia.

By Proactive Investors
November 29, 2022

FSD Pharma announces changes to its board of directors

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) has announced the appointments of Dr Lakshmi P. Kotra and Joseph L.

By Proactive Investors
September 6, 2022

FSD Pharma wins FDA and Health Canada approval for IND for Phase 2 Trial of FSD201 for treating inflammatory disorder

FSD Pharma Inc (CSE:HUGE, NASDAQ:HUGE) revealed that it has received a study may proceed letter for its Investigational New Drug (IND) application fr

By Proactive Investors
May 31, 2022

FSD Pharma submits IND applications to the FDA and Health Canada for Phase 2 clinical trial of FSD-201 to treat an inflammatory disorder

FSD Pharma (CSE:HUGE, NASDAQ:HUGE) Inc has announced that it has submitted Investigation New Drug applications to the US Food and Drug Administration

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.